Parexel International Corporation (PRXL)
Add to Watchlists Create an AlertPRXL Key Stats
| Income Statement | |
| Revenue TTM | 1.927B |
| Revenue Quarterly YoY Growth | 27.04% |
| EPS Diluted TTM | 1.402 |
| EPS Diluted Quarterly YoY Growth | 31.58% |
| Net Income TTM | 83.72M |
| Profitability | |
| Gross Profit Margin Quarterly | 27.24% |
| Profit Margin Quarterly | 5.64% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 2.616B |
| Enterprise Value | 2.705B |
| PE Ratio TTM | 32.82 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.3498 |
| Price / Book Value | 4.740 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.7182 |
| Free Cash Flow | 34.90M |
| Return on Equity | 14.30% |
PRXL News
- ISI Group Starts PAREXEL International (PRXL) at Neutral Street Insider May 21
- Cramer: This Fresh-Faced IPO Still a Buy May 13
- Is PAREXEL International a Cash Machine? Fool May 13
- PAREXEL INTERNATIONAL CORP Financials May 10
- Quintiles Climbs 5% In Debut In A Busy Day, Week For IPOs May 9
- Quintiles IPO Cleans Up As New Issues Multiply May 9
- Pharmaceutical services provider Quintiles surges on first day of trading May 9
- Quintiles, PennyMac, Cyan Lead Large IPO Pack May 6
- PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report May 6
- Charles River Misses Estimates in 1Q May 2
PRXL Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Parexel International Corporation is up 75.85% over the last year vs S&P 500 Total Return up 28.07%, Covance up 68.44%, and Icon up 53.24%.
PRXL Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these PRXL related companies
Pro Ratings for PRXL
Pro Report PDF for PRXL
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download PRXL Pro Report PDF
Pro Strategies Featuring PRXL
Did Parexel International Corporation make it into our Pro Portfolio Strategies?
PRXL Profile
Sector: Healthcare
Industry: Diagnostics & Research
PAREXEL International Corp. provides clinical research and development services. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The company offers contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. It also provides development and commercialization continuum services, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. The company was founded by Josef von Rickenbach in 1983 and is headquartered in Waltham, Massachusetts.
Other PRXL Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRXL | 46.02 | +0.34 | +0.74% | 2.616B |
